Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort

被引:884
作者
Froslie, Kathrine Frey
Jahnsen, Jorgen
Moum, Bjorn A.
Vatn, Morten H.
机构
[1] Univ Oslo, Rikshosp, Radium Hosp Med Ctr, Biostat Sect, N-0027 Oslo, Norway
[2] Univ Oslo, Rikshosp, Radium Hosp Med Ctr, Dept Med, N-0027 Oslo, Norway
[3] Aker Univ Hosp, Dept Med, Oslo, Norway
[4] Univ Oslo, Fac Med, Epi Gen Ahus, Oslo, Norway
关键词
D O I
10.1053/j.gastro.2007.05.051
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background&Aims: Mucosal healing (MH) in inflammatory bowel disease may be an important sign of efficacy of treatment and a prognostic marker of long-term disease. The aim of the study was to examine both the possible predictors of mucosal healing and the impact of healing on subsequent course of disease. Methods: In 740 incident patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) between 1990 and 1994 (before biologic therapy was available), demographics and symptoms were recorded. Clinical and endoscopic evaluations were done at baseline before treatment and repeated after 1 and 5 years in 495 patients. Results: In UC patients, education longer than 12 years and extensive disease at diagnosis were significant predictors of MH after 1 year (adjusted P =.004 and P = .02, respectively). MH was significantly associated with a low risk of future colectomy (P = .02). In patients with CD, fever at diagnosis and medical treatment without steroids were significant predictors for MH (adjusted P = .03 and P = .01, respectively). MH was significantly associated with less inflammation after 5 years (P = .02), decreased future steroid treatment (P =.02). Conclusions: Several factors predicted subsequent MH. Education as predictor may implicate the importance of coping, compliance, or lifestyle. MH after 1 year of treatment is predictive of reduced subsequent disease activity and decreased need for active treatment. The present results give further strength to the use of mucosal healing as a clinical indicator and treatment goal in inflammatory bowel disease.
引用
收藏
页码:412 / 422
页数:11
相关论文
共 13 条
[1]  
Altman DG., 1990, PRACTICAL STAT MED R
[2]   Mucosal healing in pediatric Crohn's disease - The goal of medical treatment [J].
D'Haens, G .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (04) :479-480
[3]   Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis [J].
de Lange, T ;
Larsen, S ;
Aabakken, L .
BMC GASTROENTEROLOGY, 2004, 4 (1)
[4]  
Fox J, 2002, COX PROPORTIONAL HAZ
[5]   Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial [J].
Hanauer, SB ;
Sandborn, WJ ;
Kornbluth, A ;
Katz, S ;
Safdi, M ;
Woogen, S ;
Regalli, G ;
Yeh, C ;
Smith-Hall, N ;
Ajayi, F .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11) :2478-2485
[6]   Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].
Hanauer, SB ;
Feagan, BG ;
Lichtenstein, GR ;
Mayer, LF ;
Schreiber, S ;
Colombel, JF ;
Rachmilewitz, D ;
Wolf, DC ;
Olson, A ;
Bao, WH ;
Rutgeerts, P .
LANCET, 2002, 359 (9317) :1541-1549
[7]  
Hosmer W., 2000, Applied Logistic Regression, VSecond
[8]   A randomized, douuble-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine [J].
Lémann, M ;
Mary, JY ;
Colombel, JF ;
Duclos, B ;
Soule, JC ;
Lerebours, E ;
Modigliani, R ;
Bouhnik, Y .
GASTROENTEROLOGY, 2005, 128 (07) :1812-1818
[9]   CLASSIFICATION OF INFLAMMATORY BOWEL-DISEASE [J].
LENNARDJONES, JE .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :2-6
[10]   Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease [J].
Lichtenstein, GR ;
Yan, SK ;
Bala, M ;
Blank, M ;
Sands, BE .
GASTROENTEROLOGY, 2005, 128 (04) :862-869